Treatment Sequencing With CDK4/6 Inhibitors

This segment examines how clinicians decide when and how to incorporate CDK4/6 inhibitors into metastatic breast cancer treatment. Panelists explain that first-line use remains standard for most eligible patients, but subsequent sequencing depends on prior exposure, disease progression patterns, and tolerance. Selecting the right sequence helps maximize both duration of response and quality of life.

Patient characteristics such as age, comorbidities, and organ function play crucial roles in determining which inhibitor and combination are most appropriate. The discussion also highlights how evolving survival data and guideline updates continue to shape these decisions. As more evidence accumulates, sequencing strategies are becoming increasingly individualized.

Ultimately, the goal of sequencing is to prolong disease control while minimizing toxicity. Multidisciplinary coordination and shared decision-making ensure that therapy remains patient-centered throughout the continuum of care.